IHC & ISH
NeoTYPE™ Cancer Profiles
NeoGenomics Laboratories is a leader in precision diagnostics and is at the forefront of PD-L1/PD-1 immunotherapy testing. PD-L1 testing is an immunohistochemical assay that detects the level and expression sites of PD-L1 protein. As a companion/complementary diagnostic for certain tumors and indications, it helps identify patients for treatments such as KEYTRUDA®1, OPDIVO®2, and TECENTRIQ®3. Our broad offering, depth of pathology expertise and experience in immuno-oncology testing make us an ideal partner for your clinical or research testing needs.
PD-L1 IHC and PD-1 IHC can be ordered as stand-alone tests or in any combination with other IHC, FISH, or molecular tests offered. PD-L1 22C3 pharmDx IHC is also a standard component of solid tumor NeoTYPE™ Cancer Profiles, which offer multimethod analyses of broad or tumor-specific biomarker profiles.
Effective the week of February 6, NeoGenomics is replacing the PD-L1 IHC lab-developed test (LDT) with the PD-L1 22C3 pharmDx test. For non-small cell lung cancer (NSCLC) patients, this change enables FDA-approved PD-L1 testing to identify patients for treatment with Keytruda®1. PD-L1 22C3 results will be provided for other tissue types, and this testing is considered off-label. Tech-only clients who wish to sign out cases with 22C3 must complete online training from the test vendor, Agilent/Dako.
Please see our Client Notice with further information about the change and training.
FDA-Approved Assay Type
Watch Dr. Albitar’s Comparison of PD-L1 Companion,
Complementary and Laboratory Developed Tests with Molecular Profiling.